



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0230

Inventors: Mary Jo Mulligan-Kehoe

Serial No.: 10/686,428

Filing Date: October 14, 2003

Examiner: Not Yet Assigned

Group Art Unit: 1642

Title: Methods for Modulating Angiogenesis

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: February 18, 2004

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)



are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted,

Jane Massey Licata
Registration No. 32,257

Date: February 18, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Asano et al., "An Anti-Human VEGF Monoclonal Antibody, MV833, That Exhibits Potent Anti-Tumor Activity In Vivo", Hybridoma 1998 17(2):185-190	
	AB	Aleshkov et al., "Biochemical and Biophysical Studies of Reactive Center cleaved Plasminogen Activator Inhibitor Type 1", J. Biol. Chem. 1996 271(35):21231-21238	
	AC	Bijnens et al., "Expression and Characterization of Recombinant Porcine Plasminogen Activator Inhibitor-1", Thrombosis and Haemostasis 1997 77(2):350-356	
	AD	Blasi F., "Proteolysis, Cell Adhesion, Chemotaxis, and Invasiveness Are Regulated by the u-PA-u-PAR-PAI-1 System", Thrombosis and Haemostasis 1999 82(2):298-304	
	AE	Brem et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", J. Neurosurg 1991 74:441-446	
	AF	Bosma et al., "Human Plasminogen Activator Inhibitor-1 Gene", J. Biol. Chem. 1988 162(19):9129-9141	
	AG	Borgström et al., "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors In Vivo", The Prostate 1998 35:1-10	
	AH	Borgström et al., "Importance of VEGF for Breast Cancer Angiogenesis in Vivo: Implications from Intravital Microscopy of Combination Treatments with an Anti-VEGF Neutralizing Monoclonal Antibody and Doxorubicin", Anticancer Research 1999 19:4203-4214	
	AI	Cao et al., "Kringle Domains of Human Angiostatin", J. Biol. Chem. 1996 271(46):29461-29467	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Cao et al., "Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis", Proc. Natl. Acad. Sci. USA 1999 96:5728-5733	
	AK	Chang et al., "Phenotypic expression in <i>E. coli</i> of a DNA sequence coding for mouse dihydrofolate reductase", Nature 1978 275:617-624	
	AL	Chapman et al., "Macrophage Fibrinolytic Activity: Identification of Two Pathways of Plasmin Formation by Intact Cells and of a Plasminogen Activator Inhibitor", Cell 1982 28(3):653-662	
	AM	Chapman H., "Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration", Current Opinion in Cell Biology 1997 9:714-724	
	AN	Clowes et al., "Smooth Muscle Cells Express Urokinase During Mitogenesis and Tissue-Type Plasminogen Activator During Migration in Injured Rat Carotid Artery", Circulation Research 1990 67:61-67	
	AO	Colbère-Garapin et al., "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 1981 150:1-14	
	AP	Collen D., "The Plasminogen (Fibrinolytic) System", Thrombosis and Haemostasis 1999 82:165-270	
	AQ	Debrock and Declerck, "Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop", Thrombosis and Haemostasis 1998 79:456-690	
	AR	De Boer et al., "The <i>tac</i> promoter: A functional hybrid derived from the <i>trp</i> and <i>lac</i> promoters", Natl. Proc. Acad. Sci. USA 1983 80:32-36	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Declerck et al., "Identification of a Conformationally Distinct Form of Plasminogen Activator Inhibitor-1, Acting as a Non-inhibitory Substrate for Tissue-type Plasminogen Activator", J. Biol. Chem. 1992 267(17):11693-11696	
	AT	Deryugina et al., "Up-Regulation of Vascular Endothelial Growth Factor by Membrane-type 1 Matrix Metalloproteinase Stimulates Human Glioma Xenograft Growth and Angiogenesis ¹ ", Cancer Research 2002 62(2):580-588	
	AU	Dhanabal et al., "Endostatin Induces Endothelial Cell Apoptosis", J. Biol. Chem. 1999 274(17):11721-11726	
	AV	Egelund et al., "Type-1 plasminogen-activator inhibitor Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility", Eur. J. Biochem. 1997 248(3):775-785	
	AW	Ehrlich et al., "Elucidation of Structural Requirements on Plasminogen Activator Inhibitor 1 for Binding to Heparin", J. Biol. Chem. 1992 267(16):11606-11611	
	AX	Fiers et al., "Complete nucleotide sequence of SV40 DNA", Nature 1978 273(5658):113-120	
	BA	Folkman and Klagsbrun, "Angiogenic Factors", Science 1987 235:442-447	
	BB	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules", J. Biol. Chem. 1992 267(9):6093-6098	
	BC	Goeddel et al., "Direct expression in <i>Escherichia coli</i> of a DNA sequence coding for human growth hormone", Nature 1979 281:544-548	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DC-0230	Serial No. 10/686,428
		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BD	Goeddel et al., "Synthesis of human fibroblast interferon by E. coli", Nucleic Acids Research 1980 8(18):4057-4074	
	BE	Gille et al., "Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)", J. Biol. Chem. 2001 276(5):3222-3230	
	BF	Hanahan et al., "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis", Cell 1996 86:353-364	
	BG	Hartman and Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells", Proc. Natl. Acad. Sci. USA 1988 85(21):8047-8051	
	BH	Houck et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA", Molecular Endocrinology 1991 5(12):1806-1814	
	BI	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability of Genetic and Proteolytic Mechanisms", J. Biol. Chem. 1992 267(36):26031-26037	
	BJ	Jones E., Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> ¹ , Genetics 1977 85(1):23-33	
	BK	Mulligan-Kehoe et al., "A Truncated Plasminogen Activator Inhibitor-1 Protein Induces and Inhibits Angiostatin (Kringles 1-3), a Plasminogen Cleavage Product", J. Biol. Chem. 2001 276(11):8588-8596	
	BL	Keijer et al., "The Interaction of Plasminogen Activator Inhibitor 1 With Plasminogen Activators (Tissue-Type and Urokinase-Type) and Fibrin: Localization of Interaction Sites and Physiologic Relevance" Blood 1991 78(2):409-409	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BM	Keyt et al., "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency", J. Biol. Chem. 1996 271(13):7788-7795	
	BN	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo", Nature 1993 362:841-844	
	BO	Kjøller et al., "Conformational changes of the reactive-centre loop and β -strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1", Eur. J. Biochem. 1996 241(1):38-46	
	BP	Kleinman et al., "Isolation and Characterization of Type IV Procollagen, Laminin, and Sulfate Proteoglycan from the EHS Sarcoma", Biochemistry 1982 21:6188-6193	
	BQ	Kroll et al., "A Multifunctional Prokaryotic Protein Expression System: Overproduction, Affinity Purification, and Selective Detection", DNA and Cell Biology 1993 12(5):441-453	
	BR	Laskowski et al., "Protein Inhibitors of Proteinases", Ann. Rev. Biochem. 1980 49:593-626	
	BS	Lawrence et al., "Serpine Reactive Center Loop Mobility Is Requirement for Inhibitor Function but Not for Enzyme Recognition", J. Biol. Chem. 1994 269(44):27657-27662	
	BT	Lawrence et al., "Characterization of the Binding of Different Conformational Forms of Plasminogen Activator Inhibitor-1 to Vitronectin", J. Biol. Chem. 1997 272(12):7676-7680	
	BU	Leung et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen", Science 1989 246:1313-1328	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BV	Liotta et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", Cell 1991 64:327-336	
	BW	Logan et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 1984 81:3655-3659	
	BX	Loskutoff and Curriden, "The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis", Annals of the New York Academy of Sciences 1990 598:238-247	
	BY	Lowy et al., "Isolation of Transforming DNA: Cloning the Hamster apt Gene", Cell 1980 22(3):817-823	
	BZ	List et al., "Plasminogen-Independent Initiation of the Pro-urokinase Activation Cascade in Vivo. Activation of Pro-urokinase by Glandular Kallikrein (mGK-6) in Plasminogen-Deficient Mice", Biochemistry 2000 39:508-515	
	CA	Luo et al., "Differential Inhibition of Fluid Accumulation and Tumor Growth in Two Mouse Ascites Tumors by an Antivascular Endothelial Growth Factor/Permeability Factor Neutralizing Antibody", Cancer Research 1998 58(12):2489-2691	
	CB	Merrifield R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide ¹ ", Journal American Chemical Society 1963 84:1899-2876	
	CC	Mandriota et al., "Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells", J. Biol. Chem. 1995 270(17):9709-9716	
	CD	Martiny-Baron and Marm�, "VEGF-mediated tumour angiogenesis: a new target for cancer therapy", Current Opinion in Biotechnology 1995 6:675-680	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DC-0230	Serial No. 10/686,428
		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CE	Mesiano et al., "Role of Vascular Endothelial Growth Factor in Ovarian Cancer", Am. J. Pathology 1998 153(4):1249-1256	
	CF	Mignatti et al., "In Vitro Angiogenesis on the Human Amniotic Membrane: Requirement for Basic Fibroblast Growth Factor-induced Proteinases", J. Cell Biol. 1989 108(2):671-682	
	CG	Moses et al., "The Role of Growth Factors in Vascular Cell Development and Differentiation", International Review of Cytology 1995 161:1-48	
	CH	Mottonen et al., "Structural basis of latency in plasminogen activator inhibitor-1", Nature 1992 355:270-273	
	CI	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", Cell 1994 79(2):315-328	
	CJ	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", Nature Medicine 1996 2(6):689-692	
	CK	Ort�ga et al., "Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix", Biology of the Cell 1998 90:381-390	
	CL	Padmanabhan and Sane, "Localization of a Vitronectin Binding Region of Plasminogen Activator Inhibitor-1", Thrombosis and Hemostasis 1997 73(5):739-898	
	CM	Patston and Schapira, "Low-Affinity Heparin Stimulates the Inactivation of Plasminogen Activator Inhibitor-1 by Thrombin", Blood 1994 84(4):1164-1172	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CN	Pepper et al., "Vascular Endothelial Growth Factor (VEGF) Induces Plasminogen Activators and Plasminogen Activator Inhibitor-1 in Microvascular Endothelial Cells", Biochemical and Biophysical Research Communications 1991 181(2):902-906	
	CO	Plouët et al., "Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect", J. Biol. Chem. 1997 272(20):13390-13385	
	CP	Porath J., "Immobilized Metal Ion Affinity Chromatography", Protein Expression and Purification 1992 3(4):263-281	
	CQ	Reilly et al., "Plasminogen Activator Inhibitor-1 Binds to Fibrin and Inhibits Tissue-type Plasminogen Activator-mediated Fibrin Dissolution", J. Biol. Chem. 1992 267(24):17128-17135	
	CR	Sancho et al., "Conformational Studies on Plasminogen Activator Inhibitor (PAI-1) in Active, Latent, Substrate, and Cleaved Forms", Biochemistry 1995 34:1064-1069	
	CS	Schechter and Berger, "On The Size of the Active Site in Proteases. I. PAPAIN", Biochemical and Biophysical Research Communications 1967 27(2):157-162	
	CT	Schnaper et al., "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways", J. Cell Physiology 1995 165:107-118	
	CU	Seiffert et al., "The Somatomedin B Domain of Vitronectin", J. Biol. Chem. 1994 269(4):2659-2666	
	CV	Siemeister et al., "The pivotal role of VEGF in tumor angiogenesis:Molecular facts and therapeutic opportunities", Scanner and Metastasis Reviews 1998 17(2):241-248	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CW	Seiki M., "Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion", Cancer Letters 2003 194:1-11	
	CX	Murakami et al., "Invasiveness of Hepatocellular Carcinoma Cell Lines: Contribution of Membrane-Type 1 Matrix Metalloproteinase ¹ ", Neoplasia 1999 1(5):424-430	
	CY	Sounni et al., "MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression", FASEB 2002 16(6):555-564	
	CZ	Stefansson et al., "Inhibition of Angiogenesis <i>in Vivo</i> by Plasminogen Activator Inhibitor-1", J. Biol. Chem. 2001 276(11):8135-8141	
	DA	Stinchcomb et al., "Isolation and characterisation of a yeast chromosomal replicator", Nature 1979 282(5734):39-43	
	DB	Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor", J. Biol. Chem. 1991 266(18):11947-11954	
	DC	Tucker and Gerard, "Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators", Eur. J. Biochem. 1996 237(1):180-187	
	DD	van Meijer et al., "Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)", FEBS Letters 1994 352:342-346	
	DE	van Meijer et al., "The Suicide Substrate Reaction Between Plasminogen Activator Inhibitor 1 and Thrombin Is Regulated by the Cofactors Vitronectin and Heparin", Blood 1997 90(5):1874-1882	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. DC-0230	Serial No. 10/686,428
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Mary Jo Mulligan-Kehoe	
		Filing Date October 14, 2003	Group 1642
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	DF	Wigler et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 1977 11:223-232	
	DG	Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene", Natl. Acad. Sci. USA 1980 77(6):3567-3570	
	DH	York et al., "Combinatorial Mutagenesis of the Reactive Site Region in Plasminogen Activator Inhibitor I", J. Biol. Chem. 1991 266(13):8495-8500	
	DI	Fidler et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", Cell 1994 79:185-188	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified
List of Patents and Publications
Cited by Applicant
 (Use several sheets if necessary)
 U.S. Department of Commerce

Docket No.
 DC-0230

Serial No.
 10/686,428

Applicant
 Mary Jo Mulligan-Kehoe

Filing Date
 October 14, 2003

Group
 1642

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	EA	5,830,880	11-3-98	Sedlacek et al.	514	44

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER

DATE CONSIDERED